Scholars Central

Conference abstractPublished 20 Nov 2013

CPE-deltaN: A powerful diagnostic and predictive biomarker for metastasis in different types of human cancers

Authors: Y. Peng Loh, Saravana RK. Murthy, Terence Lee, Ronnie T. Poon, Karel Pacak

Section on Cellular Neurobiology, Program on Developmental Neuroscience, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, USA Department of Surgery, University of Hong Kon, China Departm

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Metastasis is a major cause of mortality in cancer patients. Currently, few accurate biomarkers exist for predicting future metastasis to guide therapy. Here we report that CPE-deltaN, a splice isoform of the carboxypeptidase E gene is a prognostic biomarker. CPE-deltaN drives metastasis by interacting with histone deacetylase 1/2 to up-regulate expression of metastatic gene Nedd9. CPE-deltaN mRNA is elevated in human metastatic colon, breast, prostate, head and neck, glioblastoma and HCC cell lines. In clinical studies on 99 patients with hepatocellular carcinoma (HCC), a common cancer worldwide, CPEdeltaN mRNA quantification in the resected primary tumor (T) and normal surrounding tissue (N) established a T/N cut off value which predicted future intra-hepatic metastasis at 2 years with high sensitivity (92%) and specificity (76%), independent of cancer stage (J. Clin. Invest. 121:880-892, 2011). Additionally, a study on 68 patients with colorectal cancer showed that T/N of CPE-Ã?Â?N mRNA above the cutoff accurately diagnosed metastatic tumors. In another study, resected PHEO/PGLs having very high CPE-deltaN mRNA copy numbers accurately predicted future metastasis or recurrence in patients diagnosed with benign tumors at time of surgery, versus low copy numbers in post surgery, disease-free patients, with sensitivity and specificity values of 100%. Thus CPE-deltaN is a powerful biomarker for diagnosing and predicting future metastasis and recurrence in HCC, PHEO/ PGL and colorectal carcinoma patients, superior to the histopathological diagnosis currently available. On-going clinical studies suggest that CPE-deltaN is a prognostic biomarker for other types of cancers as well which will be discussed.

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Cell Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Science & Therapy
  • SubjectBiology
  • BylineArticles whose byline prints “Y. Peng Loh”
  • BylineArticles whose byline prints “Saravana RK. Murthy”
  • BylineArticles whose byline prints “Terence Lee”
  • BylineArticles whose byline prints “Ronnie T. Poon”
  • BylineArticles whose byline prints “Karel Pacak”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels